We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Cryo-Save | LSE:CRYO | London | Ordinary Share | NL0009272137 | ORD EUR0.10 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 420.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
02/4/2009 12:09 | pne - LOL - looks like stem-cell research is coming on great strides now. Makes the case for people paying to store their stem-cells from the point they are most valuable. If they can make sales then this could be huge... We wait. S | smarm | |
02/4/2009 11:36 | pneman - 7 Feb'09 - 05:07 - 27 of 34 edit Expecting/hoping this one to hit 40p in the near future. If only all my predictions were as good as this one! :-) | pneman | |
02/4/2009 11:09 | graph looking good... :) | turkey3 | |
30/3/2009 19:10 | Director buying another 30000 shares today. | gary1966 | |
24/3/2009 15:22 | Hopefully the results, director buying and broker recommendation will get this one going. Did it for me and so hopefully will do for others. Shame that the spread is so large though. | gary1966 | |
10/3/2009 09:37 | Interesting that CRYO hasn't responded to the news that Obama is funding stem cell research in US. Although CRYO doesn't operate in US, any benefit from the research will be worldwide. S | smarm | |
26/2/2009 14:52 | Just passing through. Can anyone advise if this company has any special competitive advantage that would prevent other listed or private equity companies from copying the business? Just strikes me that there could be a lot of competition and low margins in the future - rather like early day lazer eye companies. Any advice welcome. | henryatkin | |
09/2/2009 05:01 | Further director buys in jan... a certain stockbroker's 'strong buy' recommendation... the graph's momentum since mid dec. Are my expectations ill founded? | pneman | |
08/2/2009 17:41 | why expecting pneman? | arics | |
07/2/2009 05:07 | Expecting/hoping this one to hit 40p in the near future. | pneman | |
21/1/2009 11:19 | Reneuron could drag this one along with it. | peawacks | |
21/1/2009 08:32 | Well Mr Obama certainly gave the green light to stem cell research in his inaugural speech. | waldof | |
18/1/2009 21:58 | Major Glasgow trial to see if stem cells can be used to treat stroke victims. | peawacks | |
12/1/2009 18:26 | lets hope so!! | arics | |
12/1/2009 16:52 | arics: Very much a holder as we enter the defining period in VIY's existence. I am confident that some of the applications for their tech' will be validated and we should have some news quite soon. | waldof | |
10/1/2009 11:17 | Waldof, are you still encouraged by viy? Do you still hold, and are you aware of any forthcoming positive news on the oil or pipeline thing? Thanks in advance.... | arics | |
08/1/2009 11:13 | Encouraging i would think? | waldof | |
08/1/2009 10:52 | RNS Number : 3249L Cryo-Save Group NV 08 January 2009 Cryo-Save Group NV ("Cryo-Save" or "the Group") 2008 samples stored 21% up on 2007 Cryo-Save Group N.V. (AIM: CRYO), Europe's leading stem cell bank, has published its 2008 including Q4 sample storage numbers for the quarter to 31 December 2008. Cryo-Save stored 6,121 samples in Q4 2008 (Q4 2007: 6,103; Q3 2008: 6,511). The total number of samples stored for 2008 increased by 21% to 25,169 (2007: 20,814). The Group expects to publish its results for the year to 31 December 2008 during the week commencing 23 March 2009. Rob Koremans, Chief Executive, commented: "The operational fundamentals of our business remain strong with growing international markets including India. We are profitable and combined with a good cash position; these Q4 storage figures give us considerable confidence for the future development of the business." For further details: Cryo-Save Group + 31 (0) 575 548 998 Rob Koremans, Chief Executive Arnoud van Tulder, Chief Financial Officer | turkey3 | |
07/1/2009 16:06 | One look at the FINANCIALS on this stock explains why the directors cannot buy enough stock. The words 'hidden gem' are used all to frequently but in this case with good cause. | waldof | |
06/1/2009 16:07 | Good volume today... | turkey3 | |
05/1/2009 20:06 | note that the 32p buy was 25,000 shares; the 16p-19.9p buys were for 20X more so I would throw in a note of caution that since they have found that their buys were followed by a doubling of the price (while most director buys seem to pass with no positive impact) it was almost inevitable they would go in again but they seem to be buying sells from the MM's on the profit taking from the doubling Suggest await developments here. Stop loss at 29.9 | mryesyes | |
22/12/2008 17:17 | The directors must be going for 50.1%, but so far have not gone above 19.95, | mryesyes | |
18/12/2008 20:35 | Is there a potential tie-up between Vindon helathcare and Cryo-save? Apparently Vindon have just spent around £2.5m building new premises in Rochdale. Re: From Interimz - "The completion of the Group's new state-of-the-art premises at Kingsway in Rochdale represents the biggest opportunity. The useable floor space is four times larger than in the current property and the volume devoted to environmentally controlled storage is approximately six times greater. The new premises allow the Group to obtain more regulatory approvals and consequently broaden the range of drugs stored, as well as enabling it to build an on-site cryogenic storage facility." | brummy_git | |
18/12/2008 17:42 | Umm. Might be too much too soon, but my back of envelope MBO valuation could be be north of £1.40. I don't think directors and company would be buying unless they already had an investor/backer sniffing, but it's unlikely to be before end 1st Q. (my view). Not sure is much downside on MBO (except you can no longer own a share), depending on the buy out price agreed. The directors (who have been buying and own 37% +) will want to make a decent return. This is the fullfillment of their exit strategy. They obviously think they can survive downturn and with the new investment onboard and grow the company. IF it does go MBO way, I'd like to take bets they want to relist within a couple years! Second bit at the cherry | waterloo01 | |
18/12/2008 11:13 | too much, too soon ? | peawacks |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions